Eusol BiotechLtd has been growing earnings at an average annual rate of 31%, while the Biotechs industry saw earnings growing at 24.4% annually. Revenues have been growing at an average rate of 102% per year.
How Eusol BiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TPEX:6652 Revenue, expenses and earnings (TWD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
2
-40
15
32
30 Sep 25
1
-39
14
32
30 Jun 25
0
-38
13
32
31 Mar 25
0
-34
14
29
31 Dec 24
0
-31
15
26
30 Sep 24
0
-40
16
26
30 Jun 24
0
-49
17
26
31 Mar 24
0
-50
17
25
31 Dec 23
0
-52
17
25
30 Sep 23
0
-26
17
29
30 Jun 23
0
0
17
34
31 Mar 23
0
-9
21
43
31 Dec 22
0
-18
24
52
30 Sep 22
0
-61
26
68
30 Jun 22
0
-103
28
83
31 Mar 22
0
-113
27
90
31 Dec 21
0
-123
25
98
30 Sep 21
0
-117
24
93
30 Jun 21
0
-111
24
89
31 Mar 21
0
-113
23
91
31 Dec 20
0
-114
22
93
30 Sep 20
0
-115
22
94
30 Jun 20
0
-117
22
96
31 Mar 20
0
-112
23
93
31 Dec 19
0
-107
25
89
30 Sep 19
0
-123
26
104
30 Jun 19
0
-139
28
118
31 Mar 19
0
-167
29
156
31 Dec 18
0
-194
29
194
30 Sep 18
0
-222
30
221
30 Jun 18
1
-249
30
248
31 Mar 18
1
-233
31
219
31 Dec 17
1
-217
32
189
30 Sep 17
0
-171
28
146
30 Jun 17
0
-125
24
104
31 Mar 17
0
-112
21
91
31 Dec 16
0
-99
18
78
Quality Earnings: 6652 is currently unprofitable.
Growing Profit Margin: 6652 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6652 is unprofitable, but has reduced losses over the past 5 years at a rate of 31% per year.
Accelerating Growth: Unable to compare 6652's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6652 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.1%).
Return on Equity
High ROE: 6652 has a negative Return on Equity (-12.25%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/04/18 02:03
End of Day Share Price
2026/04/09 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eusol Biotech Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.